Latest Advances in Lung Cancer Research

Study shows 70 Gy radiation doses for lung cancer don’t increase pneumonitis risk and may improve survival compared to lower doses.

Dr. Suresh Ramalingam, a top cancer expert at Emory University, urges community oncologists to prioritize biomarker testing and lung cancer screening to ensure every patient benefits from the latest treatment breakthroughs — because advances only matter if all patients can access them.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.

Dr. Suresh S. Ramalingam urges community oncologists to use molecular testing and expand lung-cancer screening — so more patients gain access to modern, personalized therapies.

Research develops hypoxic gene expression signatures to predict which muscle-invasive bladder cancer patients will respond to hypoxia-modifying therapies.

A new study shows adding immunotherapy to chemotherapy before lung cancer surgery significantly improves five-year survival rates in patients.

Study of 1,143 lung cancer patients shows improved MET exon 14 mutation detection methods help select better targeted treatments.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

New AI model Sybil predicts future lung cancer risk from a single CT scan, offering hope for personalized screening, especially for Asian never-smokers.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

Study reveals lung cancer itself causes brain structural changes and cognitive impairment in patients before receiving any chemotherapy treatment.

A major Australian-Canadian lung cancer screening study found that 73% of high-risk participants had incidental findings during baseline CT scans, with 10% requiring clinical follow-up, highlighting significant inconsistencies in how these findings are reported to doctors and raising important questions about standardization as Australia prepares to launch its national screening program in 2025.